Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9HCY8

UPID:
S10AE_HUMAN

ALTERNATIVE NAMES:
S100 calcium-binding protein A14

ALTERNATIVE UPACC:
Q9HCY8; Q5RHT0

BACKGROUND:
The S100-A14 protein, an alternative name for S100 calcium-binding protein A14, is integral to regulating cell fate. It influences P53/TP53 protein levels, thereby affecting apoptosis, cell proliferation, and migration. Its unique function includes the modulation of MMP2, a protease under the transcriptional control of P53/TP53, crucial for cell migration. Unlike its S100 protein family counterparts, S100-A14 does not interact with calcium.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of S100-A14 offers a promising avenue for developing novel therapeutic approaches. Its critical role in modulating cell survival, proliferation, and migration makes it a valuable target for drug discovery, particularly in the fields of oncology and regenerative medicine.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.